Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131
Open Access
- 1 October 2009
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (10) , 3700-3707
Abstract
Context: Previous randomized trials have suggested an association between radioiodine treatment for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy (TAO). Objectives: The aim of the study was to compare the occurrence of worsening or development of TAO in patients who were treated with radioiodine or antithyroid drugs. Design: We conducted a randomized trial (TT 96) with a follow-up of 4 yr. Patients, Setting, and Intervention: Patients with a recent diagnosis of Graves’ hyperthyroidism were randomized to treatment with iodine-131 (163 patients) or 18 months of medical treatment (150 patients). Early substitution with T4 was given in both groups. Main Outcome Measure: Worsening or development of TAO was significantly more common in the iodine-131 treatment group (63 patients; 38.7%) compared with the medical treatment group (32 patients; 21.3%) (P < 0.001). Results: The risk for de novo development of TAO was greater in patients treated with iodine-131 (53 patients) than with medical treatment (23 patients). However, worsening of TAO in the 41 patients who had ophthalmopathy already before the start of treatment was not more common in the radioiodine group (10 patients) than in the medical group (nine patients). Smoking was shown to influence the risk of worsening or development of TAO, and smokers treated with radioiodine had the overall highest risk for TAO. However, in the group of smokers, worsening or development of TAO was not significantly associated with the choice of treatment for hyperthyroidism. Conclusions: Radioiodine treatment is a significant risk factor for development of TAO in Graves’ hyperthyroidism. Smokers run the highest risk for worsening or development of TAO irrespective of treatment modality. Radioiodine treatment for Graves’ hyperthyroidism (when compared to anti-thyroid drug treatment),and smoking increase the risk for the development of thyroid associated ophthalmopathy.Keywords
This publication has 22 references indexed in Scilit:
- Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*Clinical Endocrinology, 2008
- TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized studyEuropean Journal of Endocrinology, 2008
- Immunoglobulins from Patients with Graves’ Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I ReceptorThe Journal of Clinical Endocrinology & Metabolism, 2004
- Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor PathwayThe Journal of Immunology, 2003
- Relation between Therapy for Hyperthyroidism and the Course of Graves' OphthalmopathyNew England Journal of Medicine, 1998
- Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy.The Journal of Clinical Endocrinology & Metabolism, 1995
- Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?European Journal of Endocrinology, 1994
- Occurrence of Ophthalmopathy after Treatment for Graves' HyperthyroidismNew England Journal of Medicine, 1992
- Methimazole, but not Betamethasone, Prevents131I Treatment-Induced Rises in Thyrotropin Receptor Autoantibodies in Hyperthyroid Graves' Disease*The Journal of Clinical Endocrinology & Metabolism, 1986
- HYPOTHYROIDISM IN PROGRESSIVE OPHTHALMOPATHY OF GRAVES‘ DISEASEActa Ophthalmologica, 1972